Introduction
============

Heart surgery with cardiopulmonary bypass (CPB) is a primary treatment strategy for patients with coronary artery disease. As blood circulation in the myocardium is avoided during heart surgery, ischaemia-reperfusion (I/R) injury may occur during cardioplegic arrest.

A prominent characteristic of ischaemic injury is a reduced vascular endothelium-dependent vasodilation. Nitric oxide (NO) ([@b1-etm-0-0-7192]) and endothelin-1 (ET-1) ([@b2-etm-0-0-7192]) are two critical endothelium-derived factors. NO has a fundamental biological role in protecting organs (such as the heart) against I/R injury ([@b3-etm-0-0-7192]--[@b5-etm-0-0-7192]). In particular, the protective role of NO in the heart ([@b6-etm-0-0-7192]) and kidney ([@b7-etm-0-0-7192]) have been proven. Furthermore, the generation of ET-1 is aggravated under ischaemic conditions ([@b8-etm-0-0-7192]). In addition, substantial evidence has indicated that I/R injury associated with CPB is in closely linked with the systemic inflammatory response (SIRS) ([@b9-etm-0-0-7192],[@b10-etm-0-0-7192]). The important roles of inflammation have also been reported in the pathogenesis of brain ischemia ([@b11-etm-0-0-7192]--[@b13-etm-0-0-7192]). Various inflammatory factors, including soluble intercellular adhesion molecule-1 (sICAM-1) and ET-1 ([@b14-etm-0-0-7192]), participate in inflammatory processes. Furthermore, oxidative stress contributes to the pathogenesis of I/R injury ([@b15-etm-0-0-7192]).

It has been proved that the production of oxygen radicals is directly associated with major tissue and organ damage ([@b16-etm-0-0-7192]). Furthermore, toxic oxygen metabolites, including the lipid peroxidation product malondialdehyde (MDA) ([@b17-etm-0-0-7192]), exert damaging effects on multiple pathophysiological processes.

Peri-operative myocardial injury (PMI) is a type of injury that typically occurs in patients who received valve surgery ([@b18-etm-0-0-7192]). Furthermore, due to the effects of anesthetic drugs and mechanical ventilation, pulmonary compliance of the patients gradually decreases with the time of ventilation progressing. During CPB, the pulmonary function is impaired by the continuous low perfusion of the lungs and pre-flush-mediated blood dilution ([@b19-etm-0-0-7192]). Such lung I/R injury may affect the functions of other organs in the patients after the operation.

Based on these investigations, it is necessary to develop effective therapeutic interventions so as to protect against tissue injury ([@b20-etm-0-0-7192]). Remote ischaemic pre-conditioning (RIPC) has been recognized as a low-cost, non-invasive intervention method by applying brief ischaemia and reperfusion on an arm or a leg. RIPC exerts protective effects on remote tissue or organs against lethal acute I/R injury ([@b21-etm-0-0-7192]--[@b24-etm-0-0-7192]). RIPC may be achieved by performing a standard blood-pressure cuff ([@b25-etm-0-0-7192]). While the effect is not obvious under certain conditions ([@b25-etm-0-0-7192]--[@b27-etm-0-0-7192]), application of RIPC has produced beneficial outcomes in patients who received open-heart surgery ([@b27-etm-0-0-7192]--[@b30-etm-0-0-7192]) or coronary intervention ([@b31-etm-0-0-7192]). In addition, the protective effect of RIPC on the kidney has been previously demonstrated ([@b32-etm-0-0-7192]). However, whether RIPC has the capacity to prevent myocardial and lung I/R injury has remained to be fully demonstrated.

The overall objective of the present study was to investigate the protective effect of RIPC on myocardial and lung I/R injury. Furthermore, the present study aimed to elucidate the possible underlying mechanisms.

Materials and methods
=====================

### Study design

The present randomized controlled trial was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China). Written informed consent was received from each patient included in the study. Patients who received valve surgery at the First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China) between July 2012 and July 2015 were recruited. The inclusion criteria were mitral valve disease, aortic valve disease or combined valvular disease and patients with stable hemodynamic blood. The exclusion criteria were, infection, chronic lung disease, medications that may interfere with RIPC, pregnancy, renal disease, cardiac arrest during hospital admission and peripheral arterial disease affecting the limbs, complicated coronary heart disease, complicated hypertension, congenital heart valve disease, preoperative stroke, simultaneous radiofrequency ablation of atrial fibrillation and reoperate. The recruited patients were randomly divided into two groups. In the grouping process, the information regarding treatment allocation was delivered by a nurse who was not involved in the study. The investigators who analyzed the data were blinded to the treatment allocation.

### Intervention

In the RIPC and control groups, surgery was initiated after anaesthesia and completed prior to sternotomy. An intense multi-limb method was performed consisting of two 5-min cycles of simultaneous upper arm and thigh cuff inflation and deflation (simultaneous inflation to 200 mmHg, left inflation for 5 min and then deflation to 0 mmHg and left deflated for 5 min) ([@b32-etm-0-0-7192]). In the control group, patients were not subjected to any preconditioning. The intervention was performed without any arterial line on the arm, and the blood-pressure cuffs on the arms were bound up.

### Anesthesia and surgical protocol

Patients were intramuscularly injected with 0.3 mg/kg scopolamine and 0.2 mg/kg morphine at 0.5 h prior to the surgery. All patients were routinely monitored via electrocardiogram, non-invasive blood pressure, invasive radial arterial pressure, heart rate and respiration using a multifunctional monitor. Anaesthesia was induced with imidazole valium (0.1 mg/kg), sufentanyl (0.5 µg/kg), vucuronium bromide (0.15 mg/kg) and propofol (2.0 mg/kg). Mechanical ventilation was maintained by a Datex-Ohmeda Aestiva/5 anaesthesia machine (GE Healthcare, Little Chalfont, UK) with the tidal volume set at 8--10 ml/kg and the suction/call ratio set at 1:2. The normal-end tidal carbon dioxide pressure was maintained at 26--32 mmHg by setting the respiratory frequency at 11--13 breaths/min. Myocardium was protected by perfusion of cold blood cardioplegia. The concentration of K^+^ was 23--24 mmol/l. Surgery was performed with a median sternal incision. The distal ascending aorta was inserted into the arterial infusion tube. The superior and inferior venas cava were inserted into the vena cava drainage tube. The aortic valve was replaced with the atrial cavity tube, and the right superior pulmonary vein was placed in the left cardiac drainage to establish extracorporeal circulation. Mitral valve replacement was performed through the right atrial septal incision, with continuous or intermittent sutures. Aortic valve replacement was performed through the aortic root incision with intermittent suture. If the tricuspid valve has a lesion, it may be shaped or replaced at the same time. A standard CPB was performed using the *Stöckert* SIII perfusion system (Stöckert GmbH, Munich, Germany), which was followed by valve replacement. The surgery was completed and protamine was employed to achieve heparin reversal (protamine/heparin, 1-1.2:1).

### Primary and secondary endpoints

The primary endpoint of the present study was PMI. Highly sensitive cardiac troponin T (hsTnT) was detected as a marker for PMI. Furthermore, the present study had two secondary endpoints, one of which were the blood gas indexes, acute lung injury (ALI) and length of intensive care unit (ICU) stay, while the other one was length of hospital stay and major adverse cardiovascular events at 90 days (death, myocardial infarction or stroke).

### Detection of serum markers

Blood samples were collected pre-operatively (T1) and at 5 min (T2), 2 h (T3), 6 h (T4) and 24 h (T5) after CPB. hsTnT was quantitated by one-step enzyme immunoassay technology (Elecsys 2010; Roche Diagnostics, Basel, Switzerland) as described previously ([@b33-etm-0-0-7192]). hsTnT levels of ≥14 ng/l were considered to indicate severe myocardial injury. The content of sICAM-1 was determined by ELISA (sICAM-1; cat. no. 48T96T; Xitang Biotechnology, Shanghai, China) and the optical density value was recorded by a microplate reader (Multiskan Spectrum; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Furthermore, the level of ET-1 was detected using an immunoassay (ET-1; cat. no. 990826; Beijing Institute of East Asian Institute of Immunology, Beijing, China) according to the manufacturer\'s protocol. The contents of MDA and NO were measured using spectrophotometrical assays (MDA, cat. no. A003-1; NO, cat. no. A013-2; Nanjin Jiancheng Bioengineering Institute, Jiangsu, China).

### Blood gas analysis and ALI estimation

Alveolar-arterial oxygen pressure difference \[P(A-aDO~2~)\] and respiratory index (RI) were considered as blood gas indexes. The partial oxygen pressure (PaO~2~), partial CO~2~ pressure (PaCO~2~) and fraction of inspired oxygen (FiO~2~) were recorded using an i-STAT (Abbott, Princeton, NJ, USA) and used to calculate the P(A-aDO~2~) and RI using the following formulas: P(A-aDO~2~)=(Patm-PH~2~O) × FiO~2~-PaCO~2~/R-PaO~2~ and RI=P(A-aDO~2~)/PaO~2~, where Patm is the atmospheric pressure of 760 mmHg and PH~2~O is the water vapor pressure of 47 mmHg. ALI was estimated according to the diagnostic criteria of American-European Consensus Conference on the acute respiratory distress syndrome/ALI ([@b34-etm-0-0-7192]): i) PaO~2~/FiO~2~ \<300 mmHg; ii) no atelectasis, no pleural effusion and no pneumothorax; and iii) no congestive heart failure.

### Statistical analysis and sample size estimation

Values are expressed as the mean ± standard deviation. Comparison between groups was performed using Student\'s t-test or Wilcoxon Mann Whitney test for continuous variables that were normally or distributed or not, respectively. The Chi-squared and Fisher\'s Exact test were used for discontinuous variables. Two-way analysis of variance followed by Bonferroni\'s post-hoc test was used to analyze differences among groups for serum markers collected at different time-points. Assuming a statistical power of 90% and a type I error rate of 5%, this required a sample size of 120 subjects (which accommodated withdrawal or missing data-points). SPSS 20.0 (IBM Corp., Armonk, NY, USA) and GrahPad Prism 5 (GraphPad Inc., La Jolla, CA, USA) were used to analyze the data. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patients

A total of 280 patients were assessed for recruitment eligibility, and 241 patients were finally enrolled and assigned to the RIPC (n=121) or control (n=120) group ([Fig. 1](#f1-etm-0-0-7192){ref-type="fig"}). With regard to the basic characteristics, no significant difference was identified between the two groups ([Table I](#tI-etm-0-0-7192){ref-type="table"}). Furthermore, no adverse events (death, myocardial infarction or stroke) associated with the RIPC protocol were observed.

### Effect of RIPC on myocardial injury and lung injury

The baseline hsTnT levels in the two groups were similar and no significant difference was observed. It was identified that the levels of hsTnT in the RIPC group were reduced at 6 and 24 h post-CPB as compared with those in the control group (P\<0.05, [Fig. 2](#f2-etm-0-0-7192){ref-type="fig"}). P(A-aDO~2~) and RI are direct indicators of pulmonary ventilation and oxygenation function ([@b35-etm-0-0-7192]), and these two parameters exhibited an increasing trend at first, followed by a gradual decline gradual after CPB was performed in each of the two groups \[the decline occurred: P(A-aDO~2~), T4; RI, RIPC, T5, Control, T4\]. After CPB, the P(A-aDO~2~) was identified to be significantly lower in the RIPC group compared with that in the control group at the same time-points ([Table II](#tII-etm-0-0-7192){ref-type="table"}, [Fig. 3A](#f3-etm-0-0-7192){ref-type="fig"}). The RI in the control group was significantly higher than that in the RIPC group at 2, 6 and 24 h after CPB ([Table II](#tII-etm-0-0-7192){ref-type="table"}, [Fig. 3B](#f3-etm-0-0-7192){ref-type="fig"}). Furthermore, RIPC achieved a reduction in the incidence of ALI from 54.1 to 41.3% (P=0.053 vs. control group, [Table II](#tII-etm-0-0-7192){ref-type="table"}).

### Effect of RIPC on other endpoints

The length of ICU stay was shortened by the RIPC treatment (P\<0.05, [Table II](#tII-etm-0-0-7192){ref-type="table"}). The duration of the hospital stay in the RIPC group was also short, but not significant compared with that in the control group (P=0.24, [Table II](#tII-etm-0-0-7192){ref-type="table"}). In addition, no significant difference in the occurrence rate of death, myocardial infarction and stroke was identified between the RIPC and the control group ([Table II](#tII-etm-0-0-7192){ref-type="table"}).

### Effect of RIPC on inflammatory factors and oxidative stress

The release of sICAM-1 and ET-1, as well as the content of MDA increased at first in the two groups at 5 min after CPB and was further enhanced at 2 h (except for ET-1 in RIPC group), and declined thereafter. However, the extent of the increase of these factors was lower in the RIPC group compared with that in the control group at each corresponding time-point ([Fig. 3C-E](#f3-etm-0-0-7192){ref-type="fig"}). Furthermore, the NO levels were increased by the RIPC treatment compared with that in the control group at each corresponding time-point ([Fig. 3F](#f3-etm-0-0-7192){ref-type="fig"}).

Discussion
==========

In the present prospective study, it was demonstrated that RIPC decreased the PMI of patients receiving valve replacement. Certain studies have proved that RIPC has beneficial effects in terms of reducing PMI ([@b27-etm-0-0-7192],[@b28-etm-0-0-7192],[@b30-etm-0-0-7192]), which has also been demonstrated in a recent meta-analysis ([@b36-etm-0-0-7192]). However, no significant cardioprotective effect of RIPC was indicated in certain other previous studies ([@b25-etm-0-0-7192],[@b37-etm-0-0-7192]). Notably, RIPC may not reduce hsTnT levels, renal injury or ICU-support requirements in high-risk cardiac surgery in patients receiving generous doses of opioids as well as propofol and volatile anaesthesia, which differed from the effective trials. The intense technique used in the present study was more rapid (requires only 20 min) than the standard single-limb RIPC protocol (requires 40 min). Thus, it was possible to perform multi-limb RIPC prior to sternotomy. Furthermore, the different relative timing of RIPC and the concomitant therapy in patients undergoing cardiac surgery may contribute to the conflicting results among studies ([@b25-etm-0-0-7192],[@b26-etm-0-0-7192],[@b32-etm-0-0-7192]).

Another conclusion of the present study was that RIPC treatment elicited protective effects on the lung. Pulmonary artery blood flow was completely disrupted under CPB, and lung I/R injury was induced during this process. Post-operative pulmonary dysfunction has been identified as one of the most important factors contributing to the cardiac surgery-associated mortality ([@b38-etm-0-0-7192]). Pulmonary oxygenation, an important indicator for evaluating lung function when lung injury occurs, may be directly reflected by the P(A-aDO~2~) and RI ([@b35-etm-0-0-7192]). In the present study, RIPC was indicated to achieve a reduction of the P(A-aDO~2~) and RI after CPB compared with that in the control group, suggesting an improvement in the oxygenation of the patients in RIPC group. In addition, ALI may be triggered by valve replacement surgery ([@b39-etm-0-0-7192]). Although no significant difference was noted in comparison with the control group, the incidence of ALI was slightly reduced in the RIPC group. Furthermore, the length of ICU and hospital stays following cardiac surgery was shortened by RIPC. This result was in line with a previous study ([@b32-etm-0-0-7192]). In the present study, RIPC treatment also reduced kidney injury in patients after cardiac surgery ([@b32-etm-0-0-7192],[@b40-etm-0-0-7192]). All of these results proved the protective effect of RIPC on various organs.

Although the mechanisms underlying the protective effect of RIPC remain to be fully elucidated, a mechanistic model for the interaction between the pre-conditioned limb and the remote organ has been proposed ([@b22-etm-0-0-7192],[@b41-etm-0-0-7192]). Previous studies have demonstrated that ischemic pre-conditioning suppressed the inflammatory response and improved the anti-oxidant capacity of tissues ([@b42-etm-0-0-7192],[@b43-etm-0-0-7192]). In addition, the lung is highly susceptible to oxidative stress due to its large surface area ([@b44-etm-0-0-7192]). The effect of RIPC on the inflammation status and oxidation was then investigated in the present study. The results indicated that the release of sICAM-1 and ET-1 was mitigated and the content of lipid peroxidation product MDA after CPB was decreased by RIPC. These results indicated that RIPC produced a protective effect through inhibiting SIRS and oxidative stress in lung tissues. Furthermore, the decreased ET-1 in the RIPC group also suggested that the strength of myocardial constriction was closely associated with blood vessels. NO is a vasoactive factor and has relaxation effects, which were contrary to ET-1 ([@b45-etm-0-0-7192]). Consistently, it increased production of NO in the RIPC group, pointing to the improvement of pulmonary vascular tension. Taken together, it was concluded that RIPC elicits a protective effect by reducing the inflammatory status and improving the anti-oxidant capacity.

A limitation of the present study was that the effect of RIPC was not assessed in children, as all subjects were adult patients. The small-scale cohort and single-center design of the present study were further limitations of this study. Undoubtedly, the effect of RIPC should be explored on a larger scale and subjects should be recruited from multiple medical centers.

In conclusion, the present study demonstrated that RIPC alleviated PMI and lung I/R injury and may improve clinical outcomes, including shortened ICU stay, decreased hsTnT level at 6 and 24 h post-surgery, decreased P(A-aDO~2~) level beginning from 5 min post-surgery and decreased RI level beginning from 2 h post-surgery, in adult patients undergoing valve replacement. The protective effect of RIPC may be associated with the reduction of inflammation and oxidative stress. However, large-scale and multi-center randomized controlled trials should be performed in order to confirm the precise effects of RIPC.
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![Flow chart depicting the randomization and follow-up of patients. Intention-to-treat analysis included 257 patients who underwent randomization. Of the 128 cases in the RIPC group, 7 did not receive the assigned intervention. In the control group, 9 out of 129 cases did not receive the assigned intervention. The remaining 241 cases for final analysis were included in the present study. RIPC, remote ischaemic pre-conditioning.](etm-17-03-2099-g00){#f1-etm-0-0-7192}

![Serum hsTnT levels in RIPC and control groups. Time-points: T1, prior to surgery; T2, 5 min post-surgery; T3, 2 h post-surgery; T4, 6 h post-surgery; T5, 24 h post-surgery. ^\#^P\<0.01 vs. T1, \*P\<0.01 vs. Control group at corresponding time-point. hsTnT, high-sensitivity troponin-T; RIPC, remote ischaemic pre-conditioning.](etm-17-03-2099-g01){#f2-etm-0-0-7192}

![Parameters in the two groups at different time-points. (A and B) Oxygen supply represented by (A) P(A-aDO~2~) and (B) RI. (C and D) Alteration of serum markers for inflammation represented by (C) sICAM-1 and (D) ET-1. (E) Estimation of oxidative stress via determination of MDA content. (F) Release of NO in RIPC and control group groups Time-points: T1, prior to surgery; T2, 5 min post-surgery; T3, 2 h post-surgery; T4, 6 h post-surgery; T5, 24 h post-surgery. ^\#^P\<0.01 vs. T1, \*P\<0.01 vs. Control group at corresponding time-point. P(A-aDO~2~), alveolar-arterial oxygen pressure difference; RI, respiratory index; sICAM-1, soluble intercellular adhesion molecule-1; ET-1, endothelin-1; MDA, malondialdehyde; NO, nitric oxide; RIPC, remote ischaemic pre-conditioning.](etm-17-03-2099-g02){#f3-etm-0-0-7192}

###### 

Comparison of clinicopathological characteristics between the two groups.

  Characteristic                           RIPC (n=121)   Control group (n=120)
  ---------------------------------------- -------------- -----------------------
  Age (years)                              45.2±10.06     48.2±9.89
  Male sex (%)                             65 (53.7)      62 (55.0)
  Weight (kg)                              57.6±11.36     55.3±9.86
  Single/double valve                      72/49          80/40
  Left ventricular ejection fraction (%)                  
    \>55                                   93 (76.7)      91 (75.8)
    \<55                                   29 (23.9)      29 (24.1)
  NYHA class                                              
    I                                      27 (22.7)      25 (20.8)
    II                                     58 (47.9)      62 (51.7)
    III                                    31 (25.6)      33 (27.5)
    IV                                     2 (1.6)        2 (1.7)
  AVR                                      22 (18.1)      25 (20.8)
  DVR                                      47 (38.8)      47 (39.2)
  MVR                                      53 (43.8)      48 (40.0)
  Aortic clamp time (min)                  77.87±28.09    80.53±26.32
  CPB time (min)                           114.07±31.04   112.80±33.87
  Mechanical ventilation time (h)          8.8±3.64       9.2±5.7

Values are expressed as the mean ± standard deviation or n (%). RIPC, remote ischaemic pre-conditioning; NYHA, New York Heart Association; AVR, aortic valve replacement; DVR, double valve replacement; MVR, mitral valve replacement; CPB, cardiac bypass surgery.

###### 

Summary of study endpoints.

  Endpoint                      Control group (n=120)   RIPC group (n=121)   Mean difference (95% CI)    P-value
  ----------------------------- ----------------------- -------------------- --------------------------- -------------------------------------------------------
  hsTnT (µg/l)                                                                                           
    T1                          0.014±0.016             0.016±0.018          −0.002 (−0.060 to 0.064)    \>0.999
    T2                          0.020±0.011             0.022±0.013          −0.001 (−0.061 to 0.063)    \>0.999
    T3                          0.143±0.061             0.122±0.059          −0.021 (−0.083 to 0.041)    \>0.999
    T4                          0.783±0.412             0.614±0.336          −0.169 (−0.231 to −0.106)   \<0.001
    T5                          0.536±0.314             0.423±0.254          −0.113 (−0.175 to −0.050)   \<0.001
  P(A-aDO~2~) (mmHg)                                                                                     
    T1                          19.96±1.47              19.09±6.61           −0.8600 (−10.14 to 8.424)   \>0.999
    T2                          152.16±23.80            89.98±28.70          −62.18 (−71.46 to −52.90)   \<0.001
    T3                          182.70±47.74            142.3±33.17          −40.32 (−49.60 to −31.04)   \<0.001
    T4                          137.94±31.15            121.6±31.54          −16.29 (−25.57 to −7.006)   \<0.001
    T5                          82.83±26.60             56.02±18.89          −26.81 (−36.09 to −17.53)   \<0.001
  RI                                                                                                     
    T1                          0.255±0.14              0.258±0.08           0.003 (−0.079 to 0.085)     \>0.999
    T2                          0.318±0.11              0.292±0.09           −0.026 (−0.108 to 0.056)    \>0.999
    T3                          1.538±0.75              0.629±0.20           −0.909 (−0.991 to −0.826)   \<0.001
    T4                          1.057±0.34              0.739±0.22           −0.318 (−0.400 to −0.235)   \<0.001
    T5                          0.646±0.38              0.403±0.12           −0.243 (−0.325 to −0.160)   \<0.001
  ALI                           65 (54.1)               50 (41.3)            NA                          0.053^[a](#tfn3-etm-0-0-7192){ref-type="table-fn"}^
  ICU stay (h)                  72.28±10.5              53.59±8.45           NA                          \<0.001^[b](#tfn4-etm-0-0-7192){ref-type="table-fn"}^
  Hospital stay (days)          17.56±3.64              16.98±4.01           NA                          0.241^[b](#tfn4-etm-0-0-7192){ref-type="table-fn"}^
  Clinical outcome at 90 days                                                                            
    Death                       4 (3.3)                 2 (1.65)             NA                          0.446^[c](#tfn5-etm-0-0-7192){ref-type="table-fn"}^
    Myocardial infarction       2 (1.67)                1 (0.83)             NA                          0.662^[c](#tfn5-etm-0-0-7192){ref-type="table-fn"}^
    Stroke                      1 (0.83)                1 (0.83)             NA                          1.000^[c](#tfn5-etm-0-0-7192){ref-type="table-fn"}^

Mean differences, 95% CIs of the differences and P-values in different times of hsTnT, P(A-aDO~2~) and RI levels were analyzed by two-way analysis of variance.

P-value determined by chi-square test.

P-value determined by Student\'s t-test.

P-value determined by Fisher\'s Exact test. Values are expressed as the mean ± standard deviation or n (%). Time-points: T1, prior to surgery; T2, 5 min post-surgery; T3, 2 h post-surgery; T4, 6 h post-surgery; T5, 24 h post-surgery. hsTnT, high-sensitive troponin-T; P(A-aDO~2~), alveolar-arterial oxygen pressure difference; RI, respiratory index; ICU, intensive care unit; RIPC, remote ischaemic pre-conditioning; NA, not applicable; ALI, acute lung injury; CI, confidence interval.
